1-3 of 3
Keywords: acute myeloid leukaemia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets

Denise Ragusa, Liza Dijkhuis, Cristina Pina, Sabrina Tosi
Journal: Bioscience Reports
Biosci Rep (2023) 43 (1): BSR20220489.
DOI: https://doi.org/10.1042/BSR20220489
Published: 30 January 2023
...Denise Ragusa; Liza Dijkhuis; Cristina Pina; Sabrina Tosi Acute myeloid leukaemia (AML), typically a disease of elderly adults, affects 8 children per million each year, with the highest paediatric incidence in infants aged 0–2 of 18 per million. Recurrent cytogenetic abnormalities contribute...
View article titled, Mechanisms associated with t(7;12) <span class="search-highlight">acute</span> <span class="search-highlight">myeloid</span> <span class="search-highlight">leukaemia</span>: from genetics to potential treatment targets
Click here to open pdf in another window PDF for Mechanisms associated with t(7;12) <span class="search-highlight">acute</span> <span class="search-highlight">myeloid</span> <span class="search-highlight">leukaemia</span>: from genetics to potential treatment targets
Articles

Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives

Megan Wagstaff, Brandon Coke, Georgia R. Hodgkiss, Rhys G. Morgan
Journal: Bioscience Reports
Biosci Rep (2022) 42 (4): BSR20211841.
DOI: https://doi.org/10.1042/BSR20211841
Published: 21 April 2022
...Megan Wagstaff; Brandon Coke; Georgia R. Hodgkiss; Rhys G. Morgan Acute myeloid leukaemia (AML) is an aggressive disease of the bone marrow with a poor prognosis. Evidence suggests long established chemotherapeutic regimens used to treat AML are reaching the limits of their efficacy, necessitating...
View article titled, Targeting β-catenin in <span class="search-highlight">acute</span> <span class="search-highlight">myeloid</span> <span class="search-highlight">leukaemia</span>: past, present, and future perspectives
Click here to open pdf in another window PDF for Targeting β-catenin in <span class="search-highlight">acute</span> <span class="search-highlight">myeloid</span> <span class="search-highlight">leukaemia</span>: past, present, and future perspectives
Articles

CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia

Qi Zhang, Qi Han, Jie Zi, Chunhua Song, Zheng Ge
Journal: Bioscience Reports
Biosci Rep (2020) 40 (5): BSR20200008.
DOI: https://doi.org/10.1042/BSR20200008
Published: 27 May 2020
... and distributed under the Creative Commons Attribution License 4.0 (CC BY) . acute myeloid leukaemia CD37 gene expression prognosis It started a new era when the first monoclonal antibody (mAb), known as rituximab, for treatment of low-grade non-Hodgkins lymphoma was approved by the Food...
View article titled, CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia
Click here to open pdf in another window PDF for CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia